In Women's Healthcare
On the Hungarian market
Vraylar granted another six months
New target price lands
Hungarian drug maker not in an easy spot, according to Gábor Orbán
Hardly any faults with the Hungarian pharma company
A milestone for the company
As of 16 June
By HSBC
Partners sign binding term sheet for joint development
In partnership with Adalvo
New board member also elected at the General Meeting
Key data here
Trump's tariffs could hit the Hungarian pharmaceutical company too
Drugs maker expects significant growth, especially in the women's healthcare and biotech segments
Portfolio expanding
Interview with Gábor Orbán
FDA accepts license application for review
Third-quarter flash report came in
Analyst consensus available